ArticleACS pharmacology & translational science2022

Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.

Bárbara B Sousa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.